Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:degarelix
|
| gptkbp:approvalYear |
2008
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L02BX02
|
| gptkbp:CASNumber |
214766-78-6
|
| gptkbp:chemicalFormula |
C82H103ClN18O16
|
| gptkbp:form |
powder for solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Firmagon
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Ferring_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
GnRH receptor antagonist
|
| gptkbp:MedlinePlusID |
a609026
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
not for use in women |
| gptkbp:prescribes |
advanced hormone-dependent prostate cancer
|
| gptkbp:PubChem_CID |
6918537
DB06663 |
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
injection site reaction
weight gain hot flashes increased liver enzymes |
| gptkbp:UNII |
K3Z4F929H6
|
| gptkbp:usedFor |
prostate cancer
|
| gptkbp:bfsParent |
gptkb:Ferring
gptkb:Ferring_Pharmaceuticals |
| gptkbp:bfsLayer |
7
|